Business Context and Reporting Period
This Form 8-K is filed by Aadi Bioscience, Inc. (not Whitehawk Therapeutics, Inc.) on November 8, 2022. The report covers two primary events: the announcement of financial results for the fiscal quarter ended September 30, 2022, and significant changes to executive leadership and board composition effective January 1, 2023.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the financial results for the quarter ended September 30, 2022, but does not explicitly state specific values for revenue, profit, cash flow, margins, debt, or liquidity within the text of this 8-K. The filing notes that Mr. Delaney purchased 20,000 shares of common stock for $250,000 in a private placement transaction on September 26, 2022.
Material Changes and Executive Appointments
Effective January 1, 2023, the Company announced the following leadership changes:
- Neil Desai: Transitioned from President and CEO to Executive Chairman. He will continue to serve on the Board of Directors.
- Brendan Delaney: Appointed as President and CEO, replacing Dr. Desai. He will be removed from his role as Chief Operating Officer.
- Board Expansion: The Board size increased from seven to eight directors, with Mr. Delaney elected as a Class II director.
Compensation, Guidance, and Risks
Executive Compensation Agreements: Both Mr. Delaney and Dr. Desai entered into Amended and Restated Executive Employment Agreements effective January 1, 2023. Key terms include:
- Base Salary: $624,000 annually for both executives.
- Bonus: Eligible for an annual bonus up to 60% of base salary based on performance objectives.
- Equity Grants: Each received an option to purchase 150,000 shares of Common Stock. Vesting is 25% on January 1, 2024, with the remainder vesting monthly over four years.
- Severance:
- Outside Change of Control: 18 months of severance at 150% of base salary (plus bonus components for Dr. Desai) and COBRA reimbursement.
- Within Change of Control: Lump sum payment of 150% of (Base Salary + Target Bonus), COBRA reimbursement, and 100% accelerated vesting of unvested equity awards.
Guidance and Outlook: The filing text does not provide specific forward-looking guidance, revenue projections, or management commentary on future performance beyond the appointment of new leadership.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 9, 2022) for specific Q3 2022 financial metrics (revenue, net loss, cash position) which are not detailed in this 8-K text.
- Verify the impact of the leadership transition on the Company's strategic direction and commercialization plans.
- Assess the dilution impact of the 300,000 new stock options granted to the CEO and Executive Chairman.
- Confirm the terms of the September 26, 2022 PIPE Financing in which Mr. Delaney participated.
- Monitor the Company's cash burn rate given the lack of reported revenue in the filing text and the biopharmaceutical nature of the business.